prikaz prve stranice dokumenta Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation
  Preuzmi
PDF 693.62 KB
Znanstveni rad - Izvorni znanstveni rad
Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation
EP Europace, 23 (2021), 7; 1033-1041. https://doi.org/10.1093/europace/euab029
(Cryo-FIRST Investigators) Kuniss, Malte; Pavlović, Nikola; Velagić, Vedran; Hermida, Jean Sylvain; Healey, Stewart; Arena, Giuseppe; Badenco, Nicolas; Meyer, Christian; Chen, Jian; Iacopino, Saverio; Anselme, Frédéric; Packer, Douglas L.; Pitschner, Heinz-Friedrich; Asmundis, Carlo de; Willems, Stephan; Di Piazza, Fabio; Becker, Daniel; Chierchia, Gian-Battista Više autora...

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Kuniss, M., Pavlović, N., Velagić, V., Hermida, J. S., Healey, S., Arena, G. ... Chierchia, G. B. (2021). Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. EP Europace, 23. (7), 1033-1041. doi: 10.1093/europace/euab029

Kuniss, Malte, et al. "Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation." EP Europace, vol. 23, br. 7, 2021, str. 1033-1041. https://doi.org/10.1093/europace/euab029

Kuniss, Malte, Nikola Pavlović, Vedran Velagić, Jean Sylvain Hermida, Stewart Healey, Giuseppe Arena, Nicolas Badenco, et al. "Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation." EP Europace 23, br. 7 (2021): 1033-1041. https://doi.org/10.1093/europace/euab029

Kuniss, M., et al. (2021) 'Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation', EP Europace, 23(7), str. 1033-1041. doi: 10.1093/europace/euab029

Kuniss M, Pavlović N, Velagić V, Hermida JS, Healey S, Arena G, i sur.. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. EP Europace [Internet]. 18.07.2021. [pristupljeno 30.11.2024.];23(7):1033-1041. doi: 10.1093/europace/euab029

M. Kuniss, et al., "Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation", EP Europace, vol. 23, br. 7, str. 1033-1041, Srpanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:223841. [Citirano: 30.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:223841
Podaci o radu
Naslov (engleski)Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation
AutorMalte Kuniss
AutorNikola Pavlović
AutorVedran Velagić
AutorJean Sylvain Hermida
AutorStewart Healey
AutorGiuseppe Arena
AutorNicolas Badenco
AutorChristian Meyer
AutorJian Chen
AutorSaverio Iacopino
AutorFrédéric Anselme
AutorDouglas L. Packer
AutorHeinz-Friedrich Pitschner
AutorCarlo de Asmundis
AutorStephan Willems
AutorFabio Di Piazza
AutorDaniel Becker
AutorGian-Battista Chierchia
KolaboracijaCryo-FIRST Investigators
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Aims: Treatment guidelines for patients with atrial fibrillation (AF) suggest that patients should be managed with an antiarrhythmic drug (AAD) before undergoing catheter ablation (CA). This study evaluated whether pulmonary vein isolation employing cryoballoon CA is superior to AAD therapy for the prevention of atrial arrhythmia (AA) recurrence in rhythm control naive patients with paroxysmal AF (PAF). ----- Methods and results: A total of 218 treatment naive patients with symptomatic PAF were randomized (1 : 1) to cryoballoon CA (Arctic Front Advance, Medtronic) or AAD (Class I or III) and followed for 12 months. The primary endpoint was ≥1 episode of recurrent AA (AF, atrial flutter, or atrial tachycardia) >30 s after a prespecified 90-day blanking period. Secondary endpoints included the rate of serious adverse events (SAEs) and recurrence of symptomatic palpitations (evaluated via patient diaries). Freedom from AA was achieved in 82.2% of subjects in the cryoballoon arm and 67.6% of subjects in the AAD arm (HR = 0.48, P = 0.01). There were no group differences in the time-to-first (HR = 0.76, P = 0.28) or overall incidence [incidence rate ratio (IRR)=0.79, P = 0.28] of SAEs. The incidence rate of symptomatic palpitations was lower in the cryoballoon (7.61 days/year) compared with the AAD arm (18.96 days/year; IRR = 0.40, P < 0.001). ----- Conclusions: Cryoballoon CA was superior to AAD therapy, significantly reducing AA recurrence in treatment naive patients with PAF. Additionally, cryoballoon CA was associated with lower symptom recurrence and a similar rate of SAEs compared with AAD therapy.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEP Europace
Brojčani podacivol. 23, br. 7, str. 1033-1041
p-ISSN1099-5129
e-ISSN1532-2092
DOIhttps://doi.org/10.1093/europace/euab029
URN:NBNurn:nbn:hr:105:223841
Datum objave publikacije2021-07-18
URL dokumentahttps://academic.oup.com/europace/article/23/7/1033/6174429
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2021-10-12 08:56:42